Estimating the public health importance of the CYD-tetravalent dengue vaccine: Vaccine preventable disease incidence and numbers needed to vaccinate (Q40110796)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Estimating the public health importance of the CYD-tetravalent dengue vaccine: Vaccine preventable disease incidence and numbers needed to vaccinate	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

17 September 2017

Estimating the public health importance of the CYD-tetravalent dengue vaccine: Vaccine preventable disease incidence and numbers needed to vaccinate (English)

1 reference

Europe PubMed Central

17 September 2017

0 references

0 references

Annelies Wilder-Smith

2

object named as

Annelies Wilder-Smith

1 reference

Europe PubMed Central

17 September 2017

Bradford D Gessner

1

object named as

Bradford D Gessner

1 reference

Europe PubMed Central

17 September 2017

language of work or name

0 references

publication date

4 April 2016

1 reference

Europe PubMed Central

17 September 2017

1 reference

Europe PubMed Central

17 September 2017

34

1 reference

Europe PubMed Central

17 September 2017

20

1 reference

Europe PubMed Central

17 September 2017

2397-2401

1 reference

Europe PubMed Central

17 September 2017

The global distribution and burden of dengue

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.017

7 January 2021

Dengue: challenges for policy makers and vaccine developers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.017

7 January 2021

Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.017

7 January 2021

Efficacy of a tetravalent dengue vaccine in children in Latin America.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.017

7 January 2021

Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.017

7 January 2021

Vaccine preventable disease incidence as a complement to vaccine efficacy for setting vaccine policy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.017

7 January 2021

The number needed to vaccinate (NNV) and population extensions of the NNV: comparison of influenza and pneumococcal vaccine programmes for people aged 65 years and over

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.017

7 January 2021

Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: A double-blind randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.017

7 January 2021

Safety and Efficacy of an Attenuated Vaccine against Severe Rotavirus Gastroenteritis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.017

7 January 2021

Use of vaccines as probes to define disease burden

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.017

7 January 2021

Incidences of vaccine-preventable Haemophilus influenzae type b pneumonia and meningitis in Indonesian children: hamlet-randomised vaccine-probe trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.017

7 January 2021

Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.017

7 January 2021

What influences government adoption of vaccines in developing countries? A policy process analysis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.017

7 January 2021

Effect of Human Rotavirus Vaccine on Severe Diarrhea in African Infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.017

7 January 2021

First year experience of rotavirus immunisation programme in Finland

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.017

7 January 2021

PUBLIC HEALTH. Dengue vaccines at a crossroad

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.017

7 January 2021

Valuing the broader benefits of dengue vaccination, with a preliminary application to Brazil

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.017

7 January 2021

Age specific differences in efficacy and safety for the CYD-tetravalent dengue vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.017

7 January 2021

"Guidelines for the clinical evaluation of dengue vaccines in endemic areas": summary of a World Health Organization Technical Consultation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.017

7 January 2021

Low antibody titers 5 years after vaccination with the CYD-TDV dengue vaccine in both pre-immune and naïve vaccinees

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.017

7 January 2021

Defining the burden of pneumonia in children preventable by vaccination against Haemophilus influenzae type b

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.017

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2016.03.017

1 reference

Europe PubMed Central

17 September 2017

1 reference

Europe PubMed Central

17 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40110796&oldid=1885638312"